| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| D408749-1ml |
1ml |
现货  |
|
| 英文别名 | 1α-hydroxyvitamin D2 | (1R,3S,E)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyl-octahydroinden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol |
|---|---|
| 规格或纯度 | Moligand™, 10mM in DMSO |
| 英文名称 | Doxercalciferol |
| 生化机理 | 多钙化醇（1α-羟基维生素 D2）是一种合成维生素 D2 类似物，可抑制甲状旁腺的合成和分泌，用于治疗继发性甲状旁腺功能亢进症和代谢性骨病。 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 激动剂 |
| 作用机制 | 维生素 D 受体激动剂 |
| 产品介绍 |
Information Doxercalciferol (1α-hydroxyvitamin D2) is a syntheticvitamin D2analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease. In vivo Doxercalciferol (100 or 300 pg/g b.w.) normalizes serum calcium and parathyroid hormone (PTH) levels in nephrectomy treated mice. Doxercalciferol (300 pg/g b.w.) significantly reduces osteitis fibrosa in nephrectomy treated mice. Doxercalciferol results in significant decrease in cardiac hypertrophy and improves cardiac function in rats fed a high salt (HS) diet. Doxercalciferol treatment leads to a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level in rats fed a high salt (HS) diet. Doxercalciferol also significantly reduces the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency. Doxercalciferol decreases proteinuria, podocyte injury, mesangial expansion, and extracellular matrix protein accumulation in Diet-induced obesity (DIO) mice. Doxercalciferol also decreases macrophage infiltration, oxidative stress, proinflammatory cytokines, and profibrotic growth factors in DIO mice. Doxercalciferol also prevents the activation of the renin-angiotensin-aldosterone system including the angiotensin II type 1 receptor and the mineralocorticoid receptor in DIO mice. Doxercalciferol combined with Losartan most effectively prevents albuminuria, restored glomerular filtration barrier structure, and dramatically reduces glomerulosclerosis in a dose-dependent manner in mice. Doxercalciferol combined with Losartan virtually prevents morphological and molecular changes in diabetic kidneys of mice. cell lines： Concentrations： Incubation Time： Powder Purity:≥99% |
| Canonical SMILES | CC(C)C(C)/C=C/C(C)C1CCC2C(/CCCC12C)=C/C=C/3CC(O)CC(O)C3=C |
|---|---|
| 分子量 | 412.65 |
| Concentration | 9-11（mmol/L） |
|---|---|
| NMR Spectrum 1H | Conforms to Structure |
首页
400-620-6333
